Zoster Treatment Market Outlook:
Zoster Treatment Market size was over USD 6.5 billion in 2024 and is predicted to exceed USD 14.2 billion by the end of 2037, witnessing over 6.4% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of zoster treatment is evaluated at USD 6.9 billion.
The global zoster treatment market is expanding with an increase in the patient pool, especially seen among the elderly population. The market is further driven by the immunocompromised conditions, such as autoimmune and cancer diseases. As per the Centers for Disease Control and Prevention, over 1.2 million cases of herpes zoster are recorded yearly in the U.S., with the incidence marked mostly in patients over age 50. Further, WHO forecasts that the population aged 60 and older will double by 2050, directly contributing to increased treatment demand. This increasing burden necessitates for streamlined and responsive drug supply chain. The supply chain issues have been reported by the U.S. FDA Drug Shortages Database in the antiviral drugs such as Acyclovir and Valacyclovir due to changes in the active pharmaceutical ingredient.
According to the U.S. Bureau of Labor Statistics, the producer price index has increased 2.5% for pharmaceutical preparations in 2024, impacted by the higher input costs, while the consumer price index rose 2.2% for prescription drugs every year, showing a pricing pressure on zoster treatments. The investments in research and development are rising continuously and are driven by national health funding agencies, along with NIH, and allocated USD 66.5 million toward herpesvirus-related diseases in 2024. This funding has also supported the innovation in vaccine adjuvant systems and long-acting antivirals. According to trade statistics from the US Census Bureau and EUROSTAT, North America and Europe have imported more than USD 1.7 billion in shingles-related pharmaceutical items and precursors in 2023.
